Identification of a biochemical difference between male and female human fibroblasts
Implications for the expression of Duchenne muscular dystrophy
Citation Manager Formats
Make Comment
See Comments
![Loading Loading](https://n.neurology.org/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif)
Abstract
The lysosomal enzyme dipeptidyl aminopeptidase-I (DAP-I) was reduced in Duchenne muscular dystrophy (DMD) fibroblasts to 30% of the level found in age-and sex-matched controls (p < 0.005). Structure-linked latency, defined as the increase in DAP-I activity caused by disruption of the lysosomal membrane, was also reduced in Duchenne fibroblasts to 70% of normal levels (p < 0.001). Duchenne carriers and age-and sex-matched control fibroblasts had similar DAP-I activities and latency. However, the similarity of normal and carrier female DAP-I activities was not due to elevation of the carrier female activities to levels similar to normal males, but rather to reduction of all female DAP-I activities to 30% of normal male levels (p < 0.001). This gave them comparable activities to those of the male DMD cells. One explanation for these unexpected results would require a modification of the genetics of DMD to that of a Y-influenced X-linked model.
- © 1982 by the American Academy of Neurology
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)
Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here
Purchase
Individual access to articles is available through the Add to Cart option on the article page. Access for 1 day (from the computer you are currently using) is US$ 39.00. Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means. The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use. Distributing copies (electronic or otherwise) of the article is not allowed.
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. David Beversdorf and Dr. Ryan Townley
► Watch
Related Articles
- No related articles found.